NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
NMDA activation plays an important role in learning and memory. NMDA receptors were found to
decrease in the frontal lobe and hippocampus of Alzheimer's disease and mild cognitive
function impairment. This study is a randomized, double-blind, placebo-controlled drug trial.
All patients will be allocated randomly to 2 groups: (1) NMDA enhancer: DAOI-B group
(starting dose: 250-500 mg/d); (2) placebo group. The study period is 24 weeks. The
investigators hypothesize that DAOI-B may yield better efficacy than placebo for cognitive
function in patients with mild cognitive impairment or mild Alzheimer's disease.